Navigation Links
Novel Molecular Assay for Patient Screening Detects S. aureus and Newly Emerging MRSA Strains Available in the United States

BALTIMORE, Dec. 3, 2013 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received FDA clearance to market the BD MAX™ StaphSR Assay for use on the fully-automated BD MAX™ System. The assay, with eXTended Detection Technology, accurately detects Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) DNA directly from nasal swabs, including mecA dropout mutants and new strains of MRSA that may not be detected by other assays.

The BD MAX StaphSR Assay is the first and currently the only commercially-available molecular assay in the United States that detects recently discovered MRSA strains with the mecC gene. Rapid, accurate detection of colonized patients enables effective strategies that can help reduce the risk of surgical-site infections (SSIs), improve patient safety and save healthcare costs.i,ii

"Increased accuracy in determining patient colonization with either S. aureus or MRSA can enable clinicians to implement appropriate pre-surgical prophylaxis and direct appropriate utilization of isolation and decolonization," said Dr. Tobi Karchmer, Worldwide Vice President, Medical Affairs, BD Diagnostics. "With results available in approximately two hours compared to two or more days for culture methods, the BD MAX StaphSR Assay provides accurate and timely information to help physicians ensure safe and appropriate management of surgical patients."

SSIs are the most frequent healthcare-associated infection (HAI) in the United States, occurring in about one out of every 50 operations, and constitute the greatest portion of HAI-related costs nationally. SSIs due to MRSA increase hospital length of stay for patients by an average of 23 days and cost more than $40,000 per case to treat.iii Nasal carriage of S. aureus, including MRSA, is a well-defined risk factor for subsequent infection in surgical patients. Rapid screening and targeted decolonization decreases SSIs by nearly 60 percent and improves clinical and economic outcomes for surgical patients.iv,v

With many commercial assays, SA strains carrying SCCmec where the mecA gene is absent (commonly called "dropout mutants") may be incorrectly detected as MRSA. These false positive results can lead to inappropriate use of vancomycin for surgical prophylaxis and unnecessary, expensive isolation of  MRSA strains with the recently discovered mecC gene account for nearly three percent of all new MRSA casesvii but cannot be detected by assays that do not detect that gene.viii These false negative results can lead to inappropriate surgical prophylaxis in patients who should receive vancomycin to cover for MRSA and lack of appropriate isolation precautions to prevent transmission in the operating room and during hospitalization.

The BD MAX StaphSR Assay represents an important milestone in BD's commitment to provide healthcare institutions with cutting edge assays to detect and prevent HAIs. Other HAI assays available on the BD MAX System include BD MAX™ MRSA for the detection of MRSA DNA and BD MAX™ Cdiff for the detection of toxigenic Clostridium difficile DNA. These BD MAX™ HAI Solutions combine efficiency with the flexibility to perform multiple HAI assays in the same run, allowing hospital laboratories to customize testing in response to current and future challenges in the fight against HAIs.

About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit

i Bode et al., N Engl J Med 2010;362:9-17
ii Van Rijen et al., PLoS ONE 2012;7(8): e43065
iii Zimlichman et al., JAMA Intern Med published online September 2, 1013
iv Bode et al., N Engl J Med 2010;362:9-17
v Van Rijen et al., PLoS ONE 2012;7(8): e43065
vi Blanc et al., JCM 2011;49:722-724
vii Petersen et al., Clin Micro Infect 2013;19:E16-E22
viii Shore et al., Antimicrobial Agents and Chemotherapy.  2011;55:3765-3773

Jamie Yacco
Public Relations
(201) 847-4796

SOURCE BD (Becton, Dickinson and Company)
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
2. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
3. Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies
4. Scripps Doctors Study Novel New Device to Diagnose Irregular Heart Beat
5. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. New Data Support Role of Prometheus Laboratories Novel Assay in Optimizing IBD Treatment Management
8. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
9. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
10. OICR funds Fluorinov Pharma Inc. to further develop its novel drug for the treatment of blood cancers
11. CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 3D bioprinting ... 2022, according to a new report by Grand View Research ... Disease (CKD) which demands kidney transplantation is expected to boost ... effective substitute for organ transplantation. --> 3D bioprinting ... 2022, according to a new report by Grand View Research ...
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the French ...
(Date:11/26/2015)... , November 26, 2015 ... of the "2016 Future Horizons and ... Abuse Testing Market: Supplier Shares, Country Segment ... to their offering. --> ... "2016 Future Horizons and Growth Strategies ...
Breaking Medicine Technology:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... for all, Water For Empowerment ™ attracts volunteers together who want to ... by empowering women as key stakeholders in the process. The non-profit launched its ...
(Date:11/25/2015)... ... 2015 , ... TyloHelo Inc , North America’s largest ... accessories help improve the bather experience in the sauna, and the accessories selected ... purist looking for simplicity in design to accessories that encourage a greater expression ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert is donating ... Beat ” campaign. The partnership between the two groups began in 2014 with Vitalalert ... cause. , MAP International was founded in 1954 and is an international Christian-based health ...
(Date:11/25/2015)... ... 2015 , ... On November 25, 2015, officials of Narconon Arrowhead , ... release of a new cutting edge recovery program that has been 50 years in ... and alcohol-addicted individuals with the purpose to free addicts from the symptoms and negative ...
(Date:11/25/2015)... ... 2015 , ... Smiles by Stevens is pleased to announce the ... While many patients are aware of the benefits of Botox® in the treatment of ... suffering with discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular ...
Breaking Medicine News(10 mins):